4//SEC Filing
Arkowitz David 4
Accession 0000899243-23-020077
CIK 0001609809other
Filed
Oct 30, 8:00 PM ET
Accepted
Oct 31, 9:39 PM ET
Size
12.4 KB
Accession
0000899243-23-020077
Insider Transaction Report
Form 4
Arkowitz David
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-10-27+13,209→ 179,822 total - Sale
Common Stock
2023-10-30$1.35/sh−4,066$5,489→ 175,756 total - Award
Restricted Stock Units
2023-04-27+26,418→ 26,418 total→ Common Stock (26,418 underlying) - Exercise/Conversion
Restricted Stock Units
2023-10-27−13,209→ 13,209 total→ Common Stock (13,209 underlying)
Footnotes (4)
- [F1]On February 3, 2023, the reporting person was granted an award of 26,418 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,209 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,209 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 21, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs.
- [F3]The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.35 to $1.365, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.
Documents
Issuer
Seres Therapeutics, Inc.
CIK 0001609809
Entity typeother
Related Parties
1- filerCIK 0001296999
Filing Metadata
- Form type
- 4
- Filed
- Oct 30, 8:00 PM ET
- Accepted
- Oct 31, 9:39 PM ET
- Size
- 12.4 KB